Abstract: An eye gaze and hand data capturing system for use with a human performing a manual task (such as a surgical procedure) with a hand-held instrument (such as a surgical instrument), includes subsystems for tracking pupil position head position and orientation, hand position, and force applied by the hand to an instrument, all operatively connected to a computer that repeatedly determines an eye gaze vector, the hand position and orientation, and the force applied to the instrument and records such information as a record of spatially and temporally coherent data in a database.
Type:
Grant
Filed:
September 12, 2017
Date of Patent:
October 8, 2019
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Simon Byrns, Michael Feist, Bin Zheng, Pierre Boulanger
Abstract: Compositions and methods for inhibiting the growth of Gram-negative and/or Gram-positive bacteria and pharmaceutical compositions for treating infections of such bacteria in humans and animals are provided. An exemplary method for inhibiting the growth of Gram-negative and/or Gram-positive bacteria includes contacting the bacteria or an environment containing the bacteria with a combination of bacitracin and a gallate ester. An exemplary pharmaceutical composition includes bacitracin and a gallate ester.
Type:
Grant
Filed:
September 15, 2016
Date of Patent:
September 24, 2019
Assignee:
The Governors of the University of Alberta
Abstract: An anatomical structure is segmented from images generated in an anatomical scan. A user input device is configured for manually identifying two or more seed points on a plurality of the images. An image processor is configured to identify an optimal path through seed points on the plurality of images with a graph search. The optimal path between corresponding seed points on different images defines a boundary contour, and the anatomical structure includes two or more boundary contour. The image processor is further configured to interpolate the boundary contours over a three-dimensional volume using cardinal splines.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
September 10, 2019
Assignee:
The Governors of the University of Alberta
Inventors:
Jacob Lester Jaremko, Abhilash Hareendranathan, Myles Mabee, Richard Thompson, Pierre Boulanger, Kumaradevan Punithakumar
Abstract: The present disclosure provides methods and compositions that find use in facilitating a diagnosis of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a subject. The methods and compositions involve measurement of at least one of proteins: IL-16, IL-7, VEGF, CXCL9, CX3CL1, CCL24, CCL19, and CCL11 in a body fluid sample of a subject suspected of having CFS/ME. Levels of one or more of the aforementioned proteins can be used to facilitate a diagnosis of a CFS/ME and/or confirm a diagnosis of CFS/ME. The methods and compositions of the present disclosure also find use in screening subjects for clinical trials and facilitating treatment decisions for a subject.
Type:
Grant
Filed:
January 26, 2016
Date of Patent:
September 10, 2019
Assignee:
The Governors of the University of Alberta
Inventors:
Abdolamir Landi, David Broadhurst, D. Lorne J. Tyrrell, Michael Houghton
Abstract: Methods for the diagnosis of CRC, colorectal polyps in general and adenomatous polyps in particular by measurement of metabolites in urine are described. In some embodiments, certain metabolites are identified as being elevated or reduced in concentration or quantity in subjects with CRC and/or colorectal polyps as compared with subjects without CRC or colorectal polyps. The measurement of these metabolites in urine can indicate the presence of CRC or colorectal polyps in general or adanomatous polyps in particular in a subject.
Type:
Application
Filed:
March 6, 2019
Publication date:
September 5, 2019
Applicant:
The Governors Of The University of Alberta
Abstract: Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization.
Type:
Application
Filed:
February 18, 2019
Publication date:
September 5, 2019
Applicants:
Northwestern University, The Governors of the University of Alberta
Abstract: The invention, in some aspects relates to light-activated ion channel polypeptides and encoding nucleic acids and also relates in part to compositions comprising light-activated ion channel polypeptides and methods using light-activated ion channel polypeptides to alter cell activity and function.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
August 27, 2019
Assignees:
Massachusetts Institute of Technology, The Governors of the University of Alberta, President and Fellows of Harvard College
Inventors:
Nathan Klapoetke, Edward Boyden, Yongku Cho, Brian Y. Chow, Gane K. S. Wong, Adam E. Cohen, Daniel R. Hochbaum
Abstract: The methods described herein provide an efficient way to remove and isolate short chain fatty acids from hydrocarbons that are produced upon the heating of a fatty acid resource. The short chain fatty acids can be continuously isolated and fed into the pyrolysis reactor, which in turn increases the overall efficiency of the production of the hydrocarbons. Alternatively, the short chain fatty acids can be isolated and used in other applications.
Type:
Application
Filed:
July 21, 2017
Publication date:
August 1, 2019
Applicant:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Abstract: Described herein are methods of oxidative coupling of aryl boron reagents with sp3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
July 30, 2019
Assignee:
The Governors of the University of Alberta
Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
July 16, 2019
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Abstract: The present disclosure embraces methodology and compositions for preparing pea seed coat fractions conferring improved health and/or other beneficial effects, and such fractions may be used in a human and/or animal diet.
Type:
Grant
Filed:
August 24, 2015
Date of Patent:
July 9, 2019
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Jocelyn Ozga, Catherine Chan, Alena Jin, Han Yang, Seyede Zohre Hashemi, Kaiyuan Yang
Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
May 28, 2019
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Michael Houghton, John L. Law, Michael Logan, Darren Hockman, Abdolamir Landi
Abstract: Methods for the diagnosis of CRC, colorectal polyps in general and adenomatous polyps in particular by measurement of metabolites in urine are described. In some embodiments, certain metabolites are identified as being elevated or reduced in concentration or quantity in subjects with CRC and/or colorectal polyps as compared with subjects without CRC or colorectal polyps. The measurement of these metabolites in urine can indicate the presence of CRC or colorectal polyps in general or adanomatous polyps in particular in a subject.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
April 23, 2019
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Abstract: The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.
Type:
Grant
Filed:
April 17, 2015
Date of Patent:
April 23, 2019
Assignee:
The Governors of the University of Alberta
Inventors:
Todd McMullen, Ana Lopez-Campistrous, David Williams
Abstract: The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of Campylobacter, such as C. jejuni for example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria is Escherichia coli, Salmonella or any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
April 16, 2019
Assignee:
The Governors of the University of Alberta
Abstract: A device for measuring spinal stiffness comprises a frame-work supporting a roller that is rolled over the surface of the back. The device creates and records a trajectory across a subject, using a control board and the roller, and moves the roller along the trajectory while applying a force to the subject using the roller and records displacement of the object in the direction of the force. A stiffness map is created using displacement as a function of force. Motors may be used to move the roller through three axes.
Type:
Application
Filed:
March 29, 2017
Publication date:
March 21, 2019
Applicant:
The Governors of the University of Alberta
Abstract: A method of determining risk of stress in a subject involves determining in a biological sample, the level of one or more forms of calcium binding protein spermatid specific 1 protein, wherein the one or more forms comprise one or more of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms; comparing the level of the one or more forms in the sample with the level of the one or more forms in a normal control; determining whether the subject has risk of stress in accordance with the result; wherein a difference in the level of the one or more forms relative to the level of the normal control, is indicative of stress or responsiveness to stressful stimuli; and treating the subject with a stress management program that involves using one or more forms of 12 kDa, 15 kDa, 18 kDa, 20 kDa, 27 kDa, 33 kDa, 55 kDa, or 90 kDa forms as therapeutic targets.
Type:
Application
Filed:
March 14, 2017
Publication date:
March 14, 2019
Applicant:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Inventors:
Dean BEFUS, Thomas RITZ, Chris ST. LAURENT, Katherine ST. LAURENT